The future is now: are you keeping pace with oligo synthesis optimization?

The oligonucleotide market is moving fast. Now is an exciting time with 20 therapeutics on the market and so many oligos being developed for future treatments. While the market traditionally centred around the outstanding and essential work with rare diseases, some blockbusters are emerging for much larger patient indications.

We know that you’re the expert in your molecule and have the ambition to advance healthcare and treat your patients. At Cytiva, we have four decades of experience and expertise in oligonucleotide manufacturing, and our prior knowledge and process experience could make a difference for your in-house R&D, process development, and scale-up. We can also help if you want to move your process in-house from a CDMO. In this presentation, we’ll share some of our key learnings and recent innovations that can help you optimize resource use and future RNA synthesis.